<DOC>
	<DOCNO>NCT00002452</DOCNO>
	<brief_summary>The purpose study see L-756423 , anti-HIV drug , safe give indinavir work well lower level HIV blood ( viral load ) .</brief_summary>
	<brief_title>A Study Safety Effectiveness L-756423 Plus Indinavir HIV-Positive Patients Who Have Previously Taken Indinavir</brief_title>
	<detailed_description>All patient receive L-756423 plus indinavir plus two license nucleoside reverse transcriptase inhibitor ( NRTIs ) , least one patient naive . Patients remain drug regimen 12 week ( possible extension 16 week ) . Patients evaluate physical examination laboratory test blood urine Weeks 1 , 2 , 4 , 6 , 8 , 12 two week post study . Plasma viral RNA measure Weeks 1 , 2 , 4 , 6 , 8 , 12 . CD4 cell count measure Weeks 2,4,8 , 12 .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Indinavir</mesh_term>
	<criteria>Inclusion Criteria You may eligible study : Are HIVpositive . Are least 18 year old . Have viral load least 1,000 copies/ml . Have CD4 cell count least 100 cells/mm3 . Have experience treatment failure ( viral load increase significantly ) within 24 week study entry take indinavir . Exclusion Criteria You eligible study : Are take nonnucleoside reverse transcriptase inhibitor ( NNRTIs ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2000</verification_date>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Indinavir</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Viral Load</keyword>
</DOC>